Literature DB >> 18927461

Multivariable analysis of outcome predictors and adjustment of main outcome results to baseline data profile in randomized controlled trials: Safe Implementation of Thrombolysis in Stroke-MOnitoring STudy (SITS-MOST).

Nils Wahlgren1, Niaz Ahmed, Niclas Eriksson, Franz Aichner, Erich Bluhmki, Antoni Dávalos, Terttu Erilä, Gary A Ford, Martin Grond, Werner Hacke, Michael G Hennerici, Markku Kaste, Martin Köhrmann, Vincent Larrue, Kennedy R Lees, Thomas Machnig, Risto O Roine, Danilo Toni, Geert Vanhooren.   

Abstract

BACKGROUND AND
PURPOSE: The Safe Implementation of Thrombolysis in Stroke-MOnitoring STudy (SITS-MOST) unadjusted results demonstrated that intravenous alteplase is well tolerated and that the effects were comparable with those seen in randomized, controlled trials (RCTs) when used in routine clinical practice within 3 hours of ischemic stroke onset. We aimed to identify outcome predictors and adjust the outcomes of the SITS-MOST to the baseline characteristics of RCTs.
METHODS: The study population was SITS-MOST (n=6483) and pooled RCTs (n=464) patients treated with intravenous alteplase within 3 hours of stroke onset. Multivariable, backward stepwise regression analyses (until P<or=0.10) were performed to identify the outcome predictors for SITS-MOST. Variables appearing either in the final multivariable model or differing (P<0.10) between SITS-MOST and RCTs were included in the prediction model for the adjustment of outcomes. Main outcome measures were symptomatic intracerebral hemorrhage, defined as National Institutes of Health Stroke Scale deterioration >or=1 within 7 days with any hemorrhage (RCT definition), mortality, and independency as defined by modified Rankin Score of 0 to 2 at 3 months.
RESULTS: The adjusted proportion of symptomatic intracerebral hemorrhage for SITS-MOST was 8.5% (95% CI, 7.9 to 9.0) versus 8.6% (6.3 to 11.6) for pooled RCTs; mortality was 15.5% (14.7 to 16.2) versus 17.3% (14.1 to 21.1); and independency was 50.4% (49.6 to 51.2) versus 50.1% (44.5 to 54.7), respectively. In the multivariable analysis, older age, high blood glucose, high National Institutes of Health Stroke Scale score, and current infarction on imaging scans were related to poor outcome in all parameters. Systolic blood pressure, atrial fibrillation, and weight were additional predictors of symptomatic intracerebral hemorrhage. Current smokers had a lower rate of symptomatic intracerebral hemorrhage. Disability before current stroke (modified Rankin Score 2 to 5), diastolic blood pressure, antiplatelet other than aspirin, congestive heart failure, patients treated in new centers, and male sex were related to high mortality at 3 months.
CONCLUSIONS: The adjusted outcomes from SITS-MOST were almost identical to those in relevant RCTs and reinforce the conclusion drawn previously in the unadjusted analysis. We identified several important outcome predictors to better identify patients suitable for thrombolysis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18927461     DOI: 10.1161/STROKEAHA.107.510768

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  102 in total

1.  The prognosis for aphasia in stroke.

Authors:  Matthew B Maas; Michael H Lev; Hakan Ay; Aneesh B Singhal; David M Greer; Wade S Smith; Gordon J Harris; Elkan F Halpern; Walter J Koroshetz; Karen L Furie
Journal:  J Stroke Cerebrovasc Dis       Date:  2010-12-24       Impact factor: 2.136

Review 2.  Timing of blood pressure lowering in acute ischemic stroke.

Authors:  Cheryl Carcel; Craig S Anderson
Journal:  Curr Atheroscler Rep       Date:  2015-08       Impact factor: 5.113

Review 3.  Imaging in Endovascular Stroke Trials.

Authors:  Konark Malhotra; David S Liebeskind
Journal:  J Neuroimaging       Date:  2015 Jul-Aug       Impact factor: 2.486

4.  Predictors and clinical relevance of hemorrhagic transformation after endovascular therapy for anterior circulation large vessel occlusion strokes: a multicenter retrospective analysis of 1122 patients.

Authors:  Raul G Nogueira; Rishi Gupta; Tudor G Jovin; Elad I Levy; David S Liebeskind; Osama O Zaidat; Ansaar Rai; Joshua A Hirsch; Daniel P Hsu; Marilyn M Rymer; Ashis H Tayal; Ridwan Lin; Sabareesh K Natarajan; Ashish Nanda; Melissa Tian; Qing Hao; Junaid S Kalia; Michael Chen; Alex Abou-Chebl; Thanh N Nguyen; Albert J Yoo
Journal:  J Neurointerv Surg       Date:  2014-01-08       Impact factor: 5.836

Review 5.  [Difficult decisions in stroke therapy].

Authors:  M Endres; M Grond; W Hacke; M Ebinger; P D Schellinger; M Dichgans
Journal:  Nervenarzt       Date:  2011-08       Impact factor: 1.214

6.  Multisociety Consensus Quality Improvement Revised Consensus Statement for Endovascular Therapy of Acute Ischemic Stroke.

Authors:  D Sacks; B Baxter; B C V Campbell; J S Carpenter; C Cognard; D Dippel; M Eesa; U Fischer; K Hausegger; J A Hirsch; M S Hussain; O Jansen; M V Jayaraman; A A Khalessi; B W Kluck; S Lavine; P M Meyers; S Ramee; D A Rüfenacht; C M Schirmer; D Vorwerk
Journal:  AJNR Am J Neuroradiol       Date:  2018-05-17       Impact factor: 3.825

7.  Factors Associated with Thrombolysis Outcome in Ischemic Stroke Patients with Atrial Fibrillation.

Authors:  Qiuyun Zhao; Xiaobo Li; Wanli Dong; Min Ye; Yongjun Cao; Meijuan Zhang; Qiantao Cheng; Junshan Zhou; Guofang Chen; Ming Yu; Shanshan Hong; Xiue Wei; Bei Wang; Guiyun Cui; Peng Zhang; Hong Ding; Rongzhen Xu; Yan Chen; Yun Xu
Journal:  Neurosci Bull       Date:  2016-03-07       Impact factor: 5.203

8.  Microalbuminuria: a potential prognostic marker for acute stroke.

Authors:  C Gumbinger; M Sykora; J Diedler; P Ringleb; A Rocco
Journal:  Nervenarzt       Date:  2012-10       Impact factor: 1.214

9.  Good clinical outcome after ischemic stroke with successful revascularization is time-dependent.

Authors:  P Khatri; T Abruzzo; S D Yeatts; C Nichols; J P Broderick; T A Tomsick
Journal:  Neurology       Date:  2009-09-29       Impact factor: 9.910

10.  A randomised controlled trial of antiplatelet therapy in combination with Rt-PA thrombolysis in ischemic stroke: rationale and design of the ARTIS-Trial.

Authors:  S M Zinkstok; M Vermeulen; J Stam; R J de Haan; Y B Roos
Journal:  Trials       Date:  2010-05-12       Impact factor: 2.279

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.